Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like ...
Tirzepatide, a once-weekly GIP/GLP-1 receptor agonist, is a medicine used for weight reduction in adults with obesity. A new analysis of the SURMOUNT clinical trials reveals that the medicine, ...
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and ...
Retatrutide is a triple agonist, meaning it targets three hormone receptor agonists: GLP-1, GIP and glucagon (GCG). It’s under investigation by manufacturer Eli Lilly to treat obesity and other health ...
Renée Fabian is Lead Editor for Pet Health at Forbes Advisor. She has over 10 years experience as a journalist and editor covering pet and human health topics. Renée previously worked as senior pet ...
Adults taking tirzepatide injection in a clinical trial lost on average 21.8 kg (48 lbs.) at the highest dose TORONTO, July 9, 2025 /CNW/ - Eli Lilly Canada is pleased to announce that ZEPBOUND™ ...
Using medications for weight loss is becoming more common. Doctors sometimes prescribe newer type 2 diabetes drugs to help with weight management. This use is “off-label,” meaning that doctors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results